Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study.

ABSTRACT

BACKGROUND: The pathogenesis of COPD is complex and remains poorly understood. The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP) investigated long-term effects of budesonide; 18% of the COPD participants were atopic. So far effects of atopy on the long-term course of COPD have not been elucidated. METHODS: Factors related to the presence of atopy (positive phadiatop) in 1277 mild-to-moderate COPD patients participating in EUROSCOP were analysed using regression analysis. Incidence and remission of respiratory symptoms during 3-year follow-up were analysed using generalised estimating equations models, and association of atopy with lung function decline using linear mixed effects models. RESULTS: Independent predisposing factors associated with the presence of atopy were male gender (OR 2.21; 95% CI 1.47-3.34), overweight/obese (OR 1.41; 95% CI 1.04-1.92) and lower age (OR 0.98; 95% CI 0.96-0.99). Atopy was associated with a higher prevalence of cough (OR 1.71; 95% CI 1.26-2.34) and phlegm (OR 1.50; 95% CI 1.10-2.03), but not with lung function levels or FEV1 decline. Atopic COPD patients not treated with budesonide had an increased incidence of cough over time (OR 1.79, 95% CI 1.03-3.08, p = 0.038), while those treated with budesonide had increased remission of cough (OR 1.93, 95% CI 1.11-3.37, p = 0.02) compared to non-atopic COPD patients. CONCLUSIONS: Atopic COPD patients are more likely male, have overweight/obesity and are younger as compared with non-atopic COPD patients. Atopy in COPD is associated with an increased incidence and prevalence of respiratory symptoms. If atopic COPD patients are treated with budesonide, they more often show remission of symptoms compared to non-atopic COPD patients who are treated with budesonide. We recommend including atopy in the diagnostic work-up and management of COPD.